when will the glp 1 pill be available Weight-loss injections are dominating market: Where GLP-1 pills fit in? Novo Nordisk's Wegovy Pill Becomes

Cho-Han Chiang, a medical oncology fellow at Northwell Health Cancer Institute, told NBC News

doi: 10.1146/annurev.immunol.021908.132710 110 KorolS

Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication

Mimics ghrelin Binds the 'hunger hormone' receptor in the pituitary gland

as of the day of this article, only Saxenda is approved for the use in weight control in Hong Kong: Dulaglutide (Trulicity) (weekly) Exenatide extended-release (Bydureon BCise) (weekly) Exenatide (Byetta) (twice daily) Semaglutide (Ozempic) (weekly) Liraglutide (Saxenda) (daily) Lixisenatide (Adlyxin) (daily) Semaglutide (Rybelsus) (oral, once daily) These drugs function by mimicking the effects of the hormone glucagon-like peptide 1

They postulate the pain felt by patients is out of proportion to the damage seen, the pain is not just because cartilage over the bone gets worn down. They state the thin rim of the cartilage becomes inflamed and sends pain signals to the body